Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()

PURPOSE: Advanced NSCLC harboring epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) typically progresses after initial response due to acquired resistance. TKIs are often continued beyond progressive disease by RECIST. We investigated the practice...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Nishino, Mizuki, Cardarella, Stephanie, Dahlberg, Suzanne E., Jackman, David M., Ramaiya, Nikhil H., Hatabu, Hiroto, Rabin, Michael S., Jänne, Pasi A., Johnson, Bruce E.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2012
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3580850/
https://ncbi.nlm.nih.gov/pubmed/23254265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2012.11.007
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items